Dual Peroxisome Proliferator–Activated Receptor α/δ Agonist GFT505 Improves Hepatic and Peripheral Insulin Sensitivity in Abdominally Obese Subjects

OBJECTIVE: The development of new insulin sensitizers is an unmet need for the treatment of type 2 diabetes. We investigated the effect of GFT505, a dual peroxisome proliferator–activated receptor (PPAR)-α/δ agonist, on peripheral and hepatic insulin sensitivity. RESEARCH DESIGN AND METHODS: Twenty-...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Cariou, Bertrand, Hanf, Rémy, Lambert-Porcheron, Stéphanie, Zaïr, Yassine, Sauvinet, Valérie, Noël, Benoit, Flet, Laurent, Vidal, Hubert, Staels, Bart, Laville, Martine
Format: Artigo
Idioma:Inglês
Publicat: American Diabetes Association 2013
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3781493/
https://ncbi.nlm.nih.gov/pubmed/23715754
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2337/dc12-2012
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars